{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:58:35Z","timestamp":1793149115443,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jhep.2025.05.031","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:10:40Z","timestamp":1751008240000},"page":"838-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"83","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Taubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakta","family":"Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nune","family":"Makarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Duggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Kajbaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Olenchock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Gansner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.05.031_bib1","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.05.031_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.05.031_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.05.031_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.05.031_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113096","article-title":"The outcomes of liver transplantation in severe metabolic dysfunction-associated steatotic liver disease patients","volume":"11","author":"Paklar","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2025.05.031_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation-fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.05.031_bib7","first-page":"87","article-title":"Challenges of organ shortage for transplantation: solutions and opportunities","volume":"5","author":"Saidi","year":"2014","journal-title":"Int J Organ Transpl Med"},{"key":"10.1016\/j.jhep.2025.05.031_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12871-019-0704-z","article-title":"Organ transplantation in the modern era","volume":"19","author":"Bezinover","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.jhep.2025.05.031_bib9","series-title":"Madrigal Pharmaceuticals","year":"2024"},{"key":"10.1016\/j.jhep.2025.05.031_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.05.031_bib11","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.05.031_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102809","article-title":"Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics","volume":"11","author":"Huang","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2025.05.031_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.05.031_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-\u03b2 dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2025.05.031_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1194\/jlr.P089953","article-title":"Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease","volume":"60","author":"Pirola","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2025.05.031_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3350\/cmh.2020.0162","article-title":"Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian cohort","volume":"27","author":"Ting","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.05.031_bib17","series-title":"Phase 1 study of the RNA interference therapeutic ALN-HSD in healthy adults and patients with nonalcoholic steatohepatitis [oral presentation]. Annual Congress of the European Association for the Study of the Liver Congress","author":"Sanyal","year":"2023"},{"key":"10.1016\/j.jhep.2025.05.031_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","article-title":"Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression","volume":"26","author":"Willoughby","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2025.05.031_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.05.031_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","article-title":"Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"60","author":"Badri","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2025.05.031_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs","volume":"64","author":"An","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2025.05.031_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2025.05.031_bib23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.05.031_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2025.05.031_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid (siRNA), givosiran, in patients with acute hepatic porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.05.031_bib26","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.05.031_bib27","unstructured":"rs72613567. Ensembl 2024. (Accessed June 4, 2024, at https:\/\/ensembl.org\/.)."},{"key":"10.1016\/j.jhep.2025.05.031_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825022706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825022706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:40:13Z","timestamp":1774860013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825022706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0168827825022706"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.05.031","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}